Gerald E. Van Strydonck - 08 Dec 2023 Form 4 Insider Report for VACCINEX, INC. (VCNX)

Role
Director
Signature
/s/ Scott E. Royer, Attorney-in-Fact for Gerald Van Strydonck
Issuer symbol
VCNX
Transactions as of
08 Dec 2023
Net transactions value
-$894
Form type
4
Filing time
12 Dec 2023, 16:31:18 UTC
Previous filing
15 May 2023
Next filing
28 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VCNX Common Stock Sale $894 -1,334 -30% $0.6700 3,149 08 Dec 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VCNX Stock Option (Right to Buy) 426 08 Dec 2023 Common Stock 426 $204.00 Direct F1
holding VCNX Stock Option (Right to Buy) 166 08 Dec 2023 Common Stock 166 $78.90 Direct F1
holding VCNX Stock Option (Right to Buy) 514 08 Dec 2023 Common Stock 514 $116.70 Direct F2
holding VCNX Stock Option (Right to Buy) 159 08 Dec 2023 Common Stock 159 $82.80 Direct F1
holding VCNX Stock Option (Right to Buy) 123 08 Dec 2023 Common Stock 123 $107.55 Direct F1
holding VCNX Stock Option (Right to Buy) 182 08 Dec 2023 Common Stock 182 $72.75 Direct F1
holding VCNX Stock Option (Right to Buy) 1,045 08 Dec 2023 Common Stock 1,045 $59.25 Direct F3
holding VCNX Stock Option (Right to Buy) 1,905 08 Dec 2023 Common Stock 1,905 $32.25 Direct F4
holding VCNX Stock Option (Right to Buy) 3,550 08 Dec 2023 Common Stock 3,550 $16.80 Direct F5
holding VCNX Stock Option (Right to Buy) 9,589 08 Dec 2023 Common Stock 9,589 $6.15 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Exercisable in full as of the date of this report.
F2 This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
F3 This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.
F4 This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first.
F5 This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first.
F6 This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first.

Remarks:

On September 25, 2023, Vaccinex, Inc. effected a 1-for-15 reverse stock split (the "Reverse Stock Split"). All figures in this Form 4 reflect the Reverse Stock Split.